<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00624416</url>
  </required_header>
  <id_info>
    <org_study_id>PBRC 27015</org_study_id>
    <nct_id>NCT00624416</nct_id>
  </id_info>
  <brief_title>Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas</brief_title>
  <official_title>A Pilot Study: Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pennington Biomedical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lipothera</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pennington Biomedical Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether injected medications will increase the amount of
      fat released by a fat cell. We will compare prednisolone (a synthetic cortisone) combined
      with isoproterenol (a drug given for asthma) versus using isoproterenol alone. We will also
      test if injections of isoproterenol and prednisolone will shrink the size of lipomas, which
      are benign fatty tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lipomas are benign, non-cancerous fatty tumors that occur under the skin and make a bump that
      can be easily felt and often seen. The current treatment for lipomas is surgery.
      Isoproterenol, a medication used for the treatment of asthma and approved for injection under
      the skin, is known to cause fat cells to give up their fat. The fat cells become resistant to
      isoproterenol with repeated use. Prednisolone, a synthetic cortisone medication used to treat
      immune problems like allergy and approved for injection under the skin, keeps the fat cells
      from becoming resistant to isoproterenol. It is not known, if the fat cells in lipomas act
      like other fat cells or if the combination of isoproterenol and prednisolone injections would
      shrink lipomas without surgery. This study is designed to test this possibility.

      Subjects will have a screening visit, 2 microdialysis visits a week apart, 20 treatment
      visits 5 days per week for 4 weeks, and up to 12 follow-up visits a year after treatment
      visits. During screening, subjects will have a history, physical exam, blood testing,
      electrocardiogram and a pregnancy testing if female with reproductive capacity. The first
      microdialysis visit will consist of placing two microdialysis catheters under the skin after
      the area is numbed. One microdialysis catheter will be in the lipoma and the other under the
      skin 2 inches away. The microdialysis catheter will connect to a pump, isoproterenol will be
      infused and the amount of fat breakdown measured. One week later prednisolone will be
      injected into the lipoma and under the skin 2 inches away. The microdialysis visit will be
      repeated 24 hours later.

      Treatment will consist of injecting the lipoma 5 days a week with a mixture of isoproterenol
      and prednisolone in the Pennington clinic as a diabetic would inject insulin. Each week the
      blood pressure, pulse and lipoma will be measured and subjects will be asked how they feel.
      At the end of the treatment period the physical examination, blood test and electrocardiogram
      will be repeated.

      The insertion of the microdialysis probes under the skin into the fat tissue could be
      uncomfortable, but numbing medication will be injected first to prevent this problem. At
      higher doses, isoproterenol could lower blood pressure and increase pulse rate. This should
      not happen at the doses used, but blood pressure and pulse will be monitored throughout the
      study. Prednisolone, at higher doses, could decrease the body's production of cortisone. This
      should not happen at the doses being used, but cortisone in the body will be measured during
      the trial. Blood tests involve the discomfort of a needle going through the skin of the arm,
      possible bruising and rarely fainting or infection. Trained technicians and sterile needles
      will minimize these risks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Average Percent Volume Reduction in the Lipoma.</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Lipoma Increased in Volume.</measure>
    <time_frame>After four weeks of treatment up to one year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Elected to Have the Lipoma Removed.</measure>
    <time_frame>After four weeks up to one year.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Lipoma</condition>
  <arm_group>
    <arm_group_label>Prednisolone and Isoproteronol Together</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Beta-adrenergic agonists and corticosteroid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone synthetic cortisone and Isoproterenol together</intervention_name>
    <description>Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.</description>
    <arm_group_label>Prednisolone and Isoproteronol Together</arm_group_label>
    <other_name>Prednisolone combined with Isoproterenol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  You are a man or a woman between the ages of 18-60, inclusive.

          -  You have a body mass index (BMI) between 20 and less than 40 kg/m2. BMI is a number
             calculated from your height and weight.

          -  You have a lipoma (a benign fatty tumor) that is 1 inch or more in diameter under the
             skin of your abdomen or on another area of your body that is easily accessible to
             study (such as the thigh).

          -  You have not gained or lost more than 11 pounds in the last 3 months.

          -  Your exercise routine has been stable for the last 3 months or you are sedentary.
             Sedentary means you do less than 60 minutes of exercise per week.

        Exclusion Criteria:

          -  You have a history of heart or blood vessel disease.

          -  Your blood pressure is above 140/90 mmHg.

          -  You have type 1 diabetes.

          -  You have a history of kidney or liver disease.

          -  You have thyroid disease that has not been treated.

          -  You are a smoker.

          -  You use a Beta-2 (B2) adrenergic stimulator (a type of drug used to treat asthma), a
             beta adrenergic blocker (a type of drug used to treat blood pressure) or
             glucocorticoid medications (a type of drug used to treat immune system disease).

          -  You have a problem with alcoholism or other substance abuse.

          -  You are pregnant or breast feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leanne Redman, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennington Biomedical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Greenway, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Pennington Biomedical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2008</study_first_submitted>
  <study_first_submitted_qc>February 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2008</study_first_posted>
  <results_first_submitted>February 10, 2011</results_first_submitted>
  <results_first_submitted_qc>May 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 22, 2012</results_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pennington Biomedical Research Center</investigator_affiliation>
    <investigator_full_name>Frank Greenway</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Obesity therapy</keyword>
  <keyword>fat</keyword>
  <keyword>drug mechanism</keyword>
  <keyword>adipose tissue</keyword>
  <keyword>cellular pharmacology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Isoproterenol</mesh_term>
    <mesh_term>Adrenergic Agents</mesh_term>
    <mesh_term>Adrenergic Agonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prednisolone and Isoproteronol</title>
          <description>Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prednisolone and Isoproteronol</title>
          <description>Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Average Percent Volume Reduction in the Lipoma.</title>
        <time_frame>Baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone and Isoproteronol</title>
            <description>Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Average Percent Volume Reduction in the Lipoma.</title>
          <units>Percent Volume reduction (cc^3)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lipoma</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" spread="0.002" lower_limit="10" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Lipoma Increased in Volume.</title>
        <time_frame>After four weeks of treatment up to one year.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone and Isoproteronol</title>
            <description>Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Lipoma Increased in Volume.</title>
          <units>Lipomas</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lipoma</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Elected to Have the Lipoma Removed.</title>
        <time_frame>After four weeks up to one year.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone and Isoproteronol</title>
            <description>Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Elected to Have the Lipoma Removed.</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lipoma</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Prednisolone and Isoproteronol</title>
          <description>Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The single case that did not have an increase in lipoma volume showed variability which may have been because of a small lipoma making accurate measurement difficult.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Leanne Redman</name_or_title>
      <organization>Pennington Biomedical Research Center</organization>
      <phone>225-763-0947</phone>
      <email>Leanne.Redman@pbrc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

